Feld Emily, Horn Leora
Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Onco Targets Ther. 2017 Jul 24;10:3697-3708. doi: 10.2147/OTT.S97903. eCollection 2017.
Immune-checkpoint inhibitors have become valuable therapies in the treatment of patients with non-small-cell lung cancer (NSCLC). Recent clinical trials have shown promising results with regard to efficacy and toxicity profiles of these agents compared to cytotoxic chemotherapy. Nivolumab was one of the first immune-checkpoint inhibitors to demonstrate clinical activity in patients with NSCLC, and is currently approved in the US for treatment of patients with advanced squamous and nonsquamous NSCLC who have progressed on or after platinum-based chemotherapy. This review provides an update on nivolumab's pharmacology, safety, and efficacy, as established by the CheckMate trials. We also discuss specific applications and strategies for the use of nivolumab in NSCLC patients, as well as predictive biomarkers and their role in treatment selection.
免疫检查点抑制剂已成为治疗非小细胞肺癌（NSCLC）患者的重要疗法。与细胞毒性化疗相比，近期临床试验显示这些药物在疗效和毒性方面有令人鼓舞的结果。纳武单抗是最早在NSCLC患者中显示临床活性的免疫检查点抑制剂之一，目前在美国被批准用于治疗铂类化疗后进展的晚期鳞状和非鳞状NSCLC患者。本综述根据CheckMate试验对纳武单抗的药理学、安全性和疗效进行了更新。我们还讨论了纳武单抗在NSCLC患者中的具体应用和策略，以及预测性生物标志物及其在治疗选择中的作用。
